Lydia Wuarin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lydia Wuarin has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Andres Hagerman1 shared publication
- Benjamin Assouline
Intensive Care Division, Department of Acute Care Medicine, Geneva University Hospitals
1 shared publication - Christoph Huber
Department of Cardiovascular Surgery, Geneva University Hospital, Geneva, Switzerland
1 shared publication Damiano Mugnai
Département de Chirurgie, Service de Chirurgie Cardio-Vasculaire, Hôpitaux Universitaires de Genève, Geneva, Switzerland
1 shared publication- Damiano Mugnai
Service of Cardiac and Vascular Surgery, Department of Surgery, Geneva University Hospitals, rue Gabrielle Perret-Gentil 4, 1211, Geneva 14, Switzerland
1 shared publication - Didier Hannouche
Division of Orthopaedics and Trauma Surgery, Geneva University Hospitals, Geneva, Switzerland
1 shared publication
Latest Publications
- Open Access
- 7 December 2023
- Published by MDPI AG in Preprints.org
Switching from VA-ECMO to a Percutaneous Right Ventricular Assist Device as a Bridge to Recovery in a Case of Right Ventricular Myocardial Infarction
Background Acute right heart failure (RHF) is associated with high morbidity and mortality. Temporary mechanical circulatory support (tMCS) is now part of the advanced management strategy for refractory cardiogenic shock (CS). Among such support systems, VA-ECMO remains the fastest MCS system to set up. The ProtekDuo cannula can be used as a temporary and percutaneous right ventricular assist device (RVAD) in relay with VA-ECMO in the context of prolonged weaning. Case Summary This case report describes the clinical course of a 69-year-old patient who underwent elective aortic valve replacement surgery complicated by acute RHF due to iatrogenic ligation of the right coronary artery. VA-ECMO was initiated in the context of refractory cardiogenic shock. Faced with prolonged MCS weaning, due to lack of recovery of the right ventricle associated with the absence of any other therapeutic option, a percutaneous RVAD via a ProtekDuo cannula was implanted as a bridge to recovery. The ProtekDuo was gradually weaned while the patient began rehabilitation. The patient was transferred to the medical ward after 5 weeks in the ICU, stayed 5 months in an acute medical setting, went to a rehabilitation center afterward and returned home 6 months after the initial surgery without any neurological sequalae or organ failures. In total, she remained on MCS for 39 days (21 on VA-ECMO and 18 on ProtekDuo). Discussion In cases of refractory RHF, after stabilization and organ perfusion restoration under VA-ECMO, it is feasible to switch to a percutaneous RVAD, allowing early mobilization of patients during prolonged MCS weaning until the right ventricle adapts to new loading conditions.
- 7 December 2023
- Published by MDPI AG in Preprints.org
Open AccessSwitching from VA-ECMO to a Percutaneous Right Ventricular Assist Device as a Bridge to Recovery in a Case of Right Ventricular Myocardial Infarction
Background Acute right heart failure (RHF) is associated with high morbidity and mortality. Temporary mechanical circulatory support (tMCS) is now part of the advanced management strategy for refractory cardiogenic shock (CS). Among such support systems, VA-ECMO remains the fastest MCS system to set up. The ProtekDuo cannula can be used as a temporary and percutaneous right ventricular assist device (RVAD) in relay with VA-ECMO in the context of prolonged weaning. Case Summary This case report describes the clinical course of a 69-year-old patient who underwent elective aortic valve replacement surgery complicated by acute RHF due to iatrogenic ligation of the right coronary artery. VA-ECMO was initiated in the context of refractory cardiogenic shock. Faced with prolonged MCS weaning, due to lack of recovery of the right ventricle associated with the absence of any other therapeutic option, a percutaneous RVAD via a ProtekDuo cannula was implanted as a bridge to recovery. The ProtekDuo was gradually weaned while the patient began rehabilitation. The patient was transferred to the medical ward after 5 weeks in the ICU, stayed 5 months in an acute medical setting, went to a rehabilitation center afterward and returned home 6 months after the initial surgery without any neurological sequalae or organ failures. In total, she remained on MCS for 39 days (21 on VA-ECMO and 18 on ProtekDuo). Discussion In cases of refractory RHF, after stabilization and organ perfusion restoration under VA-ECMO, it is feasible to switch to a percutaneous RVAD, allowing early mobilization of patients during prolonged MCS weaning until the right ventricle adapts to new loading conditions.
- Open Access
- 8 November 2018
- Published by Springer Nature in Antimicrobial Resistance & Infection Control
- Vol. 7 (1) , 131
Should antibiotic prophylaxis before orthopedic implant surgery depend on the duration of pre-surgical hospital stay?
Background: Prolonged hospital stay before surgery is a risk for colonization with antibiotic-resistant microorganisms and possible antibiotic-resistant surgical site infections (SSI), which lacks acknowledgement in international guidelines for perioperative antibiotic prophylaxis. Method: Retrospective cohort study focusing on prophylaxis-resistant SSI in adult orthopedic implant patients; with emphasis on length of hospital stay prior to the index surgery. Results: We enrolled 611 cases of SSI (median age, 65 years; 241 females and 161 immune-suppressed) in four large implant groups: arthroplasties (n = 309), plates (n = 127), spondylodeses (n = 31), and nails (n = 46). The causative pathogen was resistant to the perioperative antibiotic prophylaxis regimen in 307 cases (307/611; 50%), but the length of pre-surgical hospitalization did not influence the incidences of prophylaxis-resistant SSIs. These incidences were (107/211;51%) for the admission day, (170/345;49%) within 10 days of delay, (19/35;54%) between 10 and 20 days, and (11/20; 55%) beyond 20 days of hospital stay before surgery. The corresponding incidences of methicillin-resistant staphylococci were 13%, 14%, 17%, and 5%, respectively. In adjusted group comparisons, the length of prior hospital stay was equally unrelated to future prophylaxis-resistant SSI (odds ratio 1.0, 95% confidence interval 0.99–1.01). Conclusions: In our retrospective cohort of orthopedic implant SSI, the length of pre-surgical hospital stay was unrelated to the incidence of prophylaxis-resistant pathogens.
- 8 November 2018
- Published by Springer Nature in Antimicrobial Resistance & Infection Control
- Vol. 7 (1) , 131
Open AccessShould antibiotic prophylaxis before orthopedic implant surgery depend on the duration of pre-surgical hospital stay?
Background: Prolonged hospital stay before surgery is a risk for colonization with antibiotic-resistant microorganisms and possible antibiotic-resistant surgical site infections (SSI), which lacks acknowledgement in international guidelines for perioperative antibiotic prophylaxis. Method: Retrospective cohort study focusing on prophylaxis-resistant SSI in adult orthopedic implant patients; with emphasis on length of hospital stay prior to the index surgery. Results: We enrolled 611 cases of SSI (median age, 65 years; 241 females and 161 immune-suppressed) in four large implant groups: arthroplasties (n = 309), plates (n = 127), spondylodeses (n = 31), and nails (n = 46). The causative pathogen was resistant to the perioperative antibiotic prophylaxis regimen in 307 cases (307/611; 50%), but the length of pre-surgical hospitalization did not influence the incidences of prophylaxis-resistant SSIs. These incidences were (107/211;51%) for the admission day, (170/345;49%) within 10 days of delay, (19/35;54%) between 10 and 20 days, and (11/20; 55%) beyond 20 days of hospital stay before surgery. The corresponding incidences of methicillin-resistant staphylococci were 13%, 14%, 17%, and 5%, respectively. In adjusted group comparisons, the length of prior hospital stay was equally unrelated to future prophylaxis-resistant SSI (odds ratio 1.0, 95% confidence interval 0.99–1.01). Conclusions: In our retrospective cohort of orthopedic implant SSI, the length of pre-surgical hospital stay was unrelated to the incidence of prophylaxis-resistant pathogens.
- 1 October 2018
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 55, 310.e1-310.e4
External Iliac Artery Endofibrosis in a Female Cyclist: A Case Report
- 1 October 2018
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 55, 310.e1-310.e4
External Iliac Artery Endofibrosis in a Female Cyclist: A Case Report